<DOC>
	<DOCNO>NCT00488449</DOCNO>
	<brief_summary>The purpose study compare effect single repeat dos GSK256073 placebo HVT subject .</brief_summary>
	<brief_title>Study Of Pharmacokinetics Pharmacodynamics Effects Of GSK256073A On Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<criteria>Inclusion criterion : Healthy Adult male females 18 55 year age , inclusive . Female subject must nonchildbearing potential Body weight &gt; 50 kg ( 110 pound ) body mass index ( BMI ) 19 31 : Subjects QTc &lt; 450 msec screening ( QTc &lt; 480 msec subject Bundle Branch Block ) . A signed date write informed consent prior admission study . The subject able understand comply protocol requirement , instruction protocolstated restriction Exclusion criterion : Systolic blood pressure &lt; 100 mmHg 150 mmHg and/or diastolic blood pressure = 100 mmHg screening . History significant cardiac arrhythmia Active peptic ulcer disease ( PUD ) and/or history PUD within 1 year . A serum uric acid concentration 8mg/dL Screening test positive H. Pylori use nonradioactive breath test History gout and/or hyperuricemia History Gilbert 's syndrome A serum creatinine concentration normal reference range History kidney stone PT and/or aPTT reference range History recurrent indigestion , stomach upset diarrhea Liver function test ( LFTs ) creatinine phosphokinase ( CPK ) 1.5X ULN Screening stool test positive occult blood Screening peripheral blood smear abnormal RBCs CBC , MCV , and/or reticulocyte count correct haemoglobin level reference range screen Reduced G6PD activity Serum haptoglobin outside reference range screen Total serum LDH &gt; 1.25 % ULN screen Positive HIV , Hepatitis B Hepatitis C screen The subject positive prestudy urine drug/ serum alcohol screen . History alcohol consumption exceed , average , 7 drinks/week woman 14 drinks/week men within 6 month first dose study medication positive alcohol test screen History use tobacco nicotine containing product within 6 month screen positive urine cotinine screen Use prescription ( include hormone replacement therapy ) nonprescription drug vitamin within 7 day 5 halflives prior administration study medication . An exception acetaminophen allow dos 2g/day . Use dietary/herbal supplement within 14 day prior treatment study medication Treatment investigational drug within 30 day 5 halflives ( whichever longer ) prior dose . Exposure four new chemical entity within 12 month prior first dose day . History sensitivity study medication , component thereof history drug allergy , opinion physician responsible , contraindicate participation . Where participation study would result donation blood excess 500 mL within 56 day period . Unwillingness male subject use condom/spermicide Pregnant nursing woman . History flushing ( &gt; 1 episode annually ) . Fasting blood glucose 110 mg/dl and/or history type I type II DM History intraocular pathology History recurrent gum bleed History bleeding haemorrhoid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Dose Escalation</keyword>
	<keyword>GSK256073A ,</keyword>
</DOC>